Stiripentol for the treatment of seizures in Dravet syndrome

References

• Dravet C, Bureau M, Oguni H, et al. Severe myoclonic epilepsy in infancy: Dravet syndrome. Adv Neurol. 2005;95:71–102.
   PubMedGoogle Scholar
• Wirrell EC, Laux L, Donner E, et al. Optimizing the diagnosis and management of Dravet syndrome: recommendations From a North American Consensus panel. Pediatr Neurol. 2017;68:18–34 e13.
   PubMed Web of Science ®Google Scholar
• Knupp KG, Scarbro S, Wilkening G, et al. Parental perception of comorbidities in children with Dravet syndrome. Pediatr Neurol. 2017;76:60–65.
   PubMed Web of Science ®Google Scholar
• Wolff M, Cassé-Perrot C, Dravet C. Severe myoclonic epilepsy of infants (Dravet syndrome): natural history and neuropsychological findings. Epilepsia. 2006;47(Suppl 2):45–48.
   PubMedGoogle Scholar
• Wu YW, Sullivan J, McDaniel SS, et al. Incidence of Dravet syndrome in a US population. Pediatrics. 2015;136(5):e1310–e1315.
   PubMed Web of Science ®Google Scholar
• Dravet C, Bureau M, Dalla Bernardina B, et al. Severe myoclonic epilepsy in infancy (Dravet syndrome) 30 years later. Epilepsia. 2011;52(Suppl 2):1–2.
   PubMedGoogle Scholar
• Marini C, Scheffer IE, Nabbout R, et al. SCN1A duplications and deletions detected in Dravet syndrome: implications for molecular diagnosis. Epilepsia. 2009;50(7):1670–1678.
   PubMed Web of Science ®Google Scholar
• Marini C, Scheffer IE, Nabbout R, et al. The genetics of Dravet syndrome. Epilepsia. 2011;52(Suppl 2):24–29.
   PubMed Web of Science ®Google Scholar
• Parihar R, Ganesh S. The SCN1A gene variants and epileptic encephalopathies. J Hum Genet. 2013;58(9):573–580.
   PubMed Web of Science ®Google Scholar
• Engel J Jr., International League Against E. A proposed diagnostic scheme for people with epileptic seizures and with epilepsy: report of the ILAE task force on classification and terminology. Epilepsia. 2001;42(6):796–803.
   PubMed Web of Science ®Google Scholar
• Brunklaus A, Ellis R, Reavey E, et al. Prognostic, clinical and demographic features in SCN1A mutation-positive Dravet syndrome. Brain. 2012;135(Pt 8):2329–2336.
   PubMed Web of Science ®Google Scholar
• Nilsson L, Farahmand BY, Persson PG, et al. Risk factors for sudden unexpected death in epilepsy: a case-control study. Lancet. 1999;353(9156):888–893.
   PubMed Web of Science ®Google Scholar
• Ryvlin P, Nashef L, Tomson T. Prevention of sudden unexpected death in epilepsy: a realistic goal? Epilepsia. 2013;54(Suppl 2):23–28.
   PubMed Web of Science ®Google Scholar
• Harden C, Tomson T, Gloss D, et al. Practice guideline summary: sudden unexpected death in epilepsy incidence rates and risk factors: report of the guideline development, dissemination, and implementation subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology. 2017;88(17):1674–1680.
   PubMed Web of Science ®Google Scholar
• Cooper MS, McIntosh A, Crompton DE, et al. Mortality in Dravet syndrome. Epilepsy Res. 2016;128:43–47.
   PubMed Web of Science ®Google Scholar
• Inoue Y, Ohtsuka Y, Oguni H, et al. Stiripentol open study in Japanese patients with Dravet syndrome. Epilepsia. 2009;50(11):2362–2368.
   PubMed Web of Science ®Google Scholar
• Dressler A, Trimmel-Schwahofer P, Reithofer E, et al. Efficacy and tolerability of the ketogenic diet in Dravet syndrome - Comparison with various standard antiepileptic drug regimen. Epilepsy Res. 2015;109:81–89.
   PubMed Web of Science ®Google Scholar
• Wu Q, Wang H, Fan YY, et al. Ketogenic diet effects on 52 children with pharmacoresistant epileptic encephalopathy: A clinical prospective study. Brain Behav. 2018;8(5):e00973.
   PubMed Web of Science ®Google Scholar
• Coppola G, Capovilla G, Montagnini A, et al. Topiramate as add-on drug in severe myoclonic epilepsy in infancy: an Italian multicenter open trial. Epilepsy Res. 2002;49(1):45–48.
   PubMed Web of Science ®Google Scholar
• Nieto-Barrera M, Candau R, Nieto-Jimenez M, et al. Topiramate in the treatment of severe myoclonic epilepsy in infancy. Seizure. 2000;9(8):590–594.
   PubMed Web of Science ®Google Scholar
• Morimoto M, Shimakawa S, Hashimoto T, et al. Marked efficacy of combined three-drug therapy (sodium valproate, topiramate and stiripentol) in a patient with Dravet syndrome. J Clin Pharm Ther. 2018;43(4):571–573.
   Web of Science ®Google Scholar
• de Lange IM, Gunning B, Sonsma ACM, et al. Influence of contraindicated medication use on cognitive outcome in Dravet syndrome and age at first afebrile seizure as a clinical predictor in SCN1A-related seizure phenotypes. Epilepsia. 2018;59(6):1154–1165.
   PubMed Web of Science ®Google Scholar
• Dalic L, Mullen SA, Roulet Perez E, et al. Lamotrigine can be beneficial in patients with Dravet syndrome. Dev Med Child Neurol. 2015;57(2):200–202.
   PubMed Web of Science ®Google Scholar
• Rilstone JJ, Coelho FM, Minassian BA, et al. Dravet syndrome: seizure control and gait in adults with different SCN1A mutations. Epilepsia. 2012;53(8):1421–1428.
   PubMed Web of Science ®Google Scholar
• Devinsky O, Cross JH, Laux L, et al. Trial of cannabidiol for drug-resistant seizures in the Dravet syndrome. N Engl J Med. 2017;376(21):2011–2020.
   PubMed Web of Science ®Google Scholar
• Devinsky O, Nabbout R, Miller I, et al. Long-term cannabidiol treatment in patients with Dravet syndrome: an open-label extension trial. Epilepsia. 2019;60(2):294–302.
   Web of Science ®Google Scholar
• Fuller RW, Snoddy HD, Robertson DW. Mechanisms of effects of d-fenfluramine on brain serotonin metabolism in rats: uptake inhibition versus release. Pharmacol Biochem Behav. 1988;30(3):715–721.
   PubMed Web of Science ®Google Scholar
• Sourbron J, Smolders I, de Witte P, et al. Pharmacological analysis of the anti-epileptic mechanisms of fenfluramine in scn1a mutant zebrafish. Front Pharmacol. 2017;8:191.
   PubMed Web of Science ®Google Scholar
• Connolly HM, Crary JL, McGoon MD, et al. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med. 1997;337(9):581–588.
   PubMed Web of Science ®Google Scholar
• Ceulemans B, Boel M, Leyssens K, et al. Successful use of fenfluramine as an add-on treatment for Dravet syndrome. Epilepsia. 2012;53(7):1131–1139.
   PubMed Web of Science ®Google Scholar
• Schoonjans A, Paelinck BP, Marchau F, et al. Low-dose fenfluramine significantly reduces seizure frequency in Dravet syndrome: a prospective study of a new cohort of patients. Eur J Neurol. 2017;24(2):309–314.
   PubMed Web of Science ®Google Scholar
• Ceulemans B, Schoonjans AS, Marchau F, et al. Five-year extended follow-up status of 10 patients with Dravet syndrome treated with fenfluramine. Epilepsia. 2016;57(7):e129–e134.
   PubMed Web of Science ®Google Scholar
• Schoonjans AS, Marchau F, Paelinck BP, et al. Cardiovascular safety of low-dose fenfluramine in Dravet syndrome: a review of its benefit-risk profile in a new patient population. Curr Med Res Opin. 2017;33(10):1773–1781.
   PubMed Web of Science ®Google Scholar
• Lagae L, Sullivan J, Cross H, et al. ZX008 (Fenfluramine) in Dravet syndrome: results of a phase 3, randomized, double-blind, placebo-controlled trial. In: editor. American epilepsy society. Houston TX; 2017.
   Google Scholar
• Griffin A, Hamling KR, Knupp K, et al. Clemizole and modulators of serotonin signalling suppress seizures in Dravet syndrome. Brain. 2017;140(3):669–683.
   PubMedGoogle Scholar
• Griffin A, Krasniak C, Baraban SC. Advancing epilepsy treatment through personalized genetic zebrafish models. Prog Brain Res. 2016;226:195–207.
   PubMed Web of Science ®Google Scholar
• Ziobro J, Eschbach K, Sullivan JE, et al. Current treatment strategies and future treatment options for dravet syndrome. Curr Treat Options Neurol. 2018;20(12):52.
   PubMed Web of Science ®Google Scholar
• Lin HS, Levy RH. Pharmacokinetic profile of a new anticonvulsant, stiripentol, in the rhesus monkey. Epilepsia. 1983;24(6):692–703.
   PubMed Web of Science ®Google Scholar
• Levy RH, Loiseau P, Guyot M, et al. Stiripentol kinetics in epilepsy: nonlinearity and interactions. Clin Pharmacol Ther. 1984;36(5):661–669.
   PubMed Web of Science ®Google Scholar
• Uchida Y, Kato D, Toyoda T, et al. Combination of ketogenic diet and stiripentol for super-refractory status epilepticus: A case report. J Neurol Sci. 2017;373:35–37.
   PubMed Web of Science ®Google Scholar
• Strzelczyk A, Kortland L-M, Knake S, et al. Stiripentol for the treatment of super-refractory status epilepticus. Acta Neurol Scand. 2015;132(6):435–439.
   PubMed Web of Science ®Google Scholar
• Merdariu D, Delanoë C, Mahfoufi N, et al. Malignant migrating partial seizures of infancy controlled by stiripentol and clonazepam. Brain Dev. 2013;35(2):177–180.
   PubMed Web of Science ®Google Scholar
• Djuric M, Kravljanac R, Kovacevic G, et al. The efficacy of bromides, stiripentol and levetiracetam in two patients with malignant migrating partial seizures in infancy. Epileptic Disord. 2011;13(1):22–26.
   PubMed Web of Science ®Google Scholar
• Quilichini PP, Chiron C, Ben-Ari Y, et al. Stiripentol, a putative antiepileptic drug, enhances the duration of opening of GABA-A receptor channels. Epilepsia. 2006;47(4):704–716.
   PubMed Web of Science ®Google Scholar
• Fisher JL. The effects of stiripentol on GABA(A) receptors. Epilepsia. 2011;52(Suppl 2):76–78.
   PubMedGoogle Scholar
• Fisher JL. The anti-convulsant stiripentol acts directly on the GABA(A) receptor as a positive allosteric modulator. Neuropharmacology. 2009;56(1):190–197.
   PubMed Web of Science ®Google Scholar
• Laurie DJ, Seeburg PH, Wisden W. The distribution of 13 GABAA receptor subunit mRNAs in the rat brain. II. Olfactory bulb and cerebellum. J Neurosci. 1992;12(3):1063–1076.
   PubMed Web of Science ®Google Scholar
• Sada N, Lee S, Katsu T, et al. Targeting LDH enzymes with a stiripentol analog to treat epilepsy. Science. 2015;347(6228):1362–1367.
   PubMed Web of Science ®Google Scholar
• Verleye M, Buttigieg D, Steinschneider R. Neuroprotective activity of stiripentol with a possible involvement of voltage-dependent calcium and sodium channels. J Neurosci Res. 2016;94(2):179–189.
   PubMed Web of Science ®Google Scholar
• Tran A, Rey E, Pons G, et al. Influence of stiripentol on cytochrome P450-mediated metabolic pathways in humans: in vitro and in vivo comparison and calculation of in vivo inhibition constants. Clin Pharmacol Ther. 1997;62(5):490–504.
   PubMed Web of Science ®Google Scholar
• Diacomit (Stiripentol) [package insert]. Biocedex, Beauvais, France. Reference ID: 4309499. 2018.
   Google Scholar
• Perez J, Chiron C, Musial C, et al. Stiripentol: efficacy and tolerability in children with epilepsy. Epilepsia. 1999;40(11):1618–1626.
   PubMed Web of Science ®Google Scholar
• Giraud C, Treluyer JM, Rey E, et al. In vitro and in vivo inhibitory effect of stiripentol on clobazam metabolism. Drug Metab Dispos. 2006;34(4):608–611.
   PubMed Web of Science ®Google Scholar
• Chiron C, Marchand MC, Tran A, et al. Stiripentol in severe myoclonic epilepsy in infancy: a randomised placebo-controlled syndrome-dedicated trial. STICLO study group. Lancet. 2000;356(9242):1638–1642.
   PubMed Web of Science ®Google Scholar
• Inoue Y, Ohtsuka Y, Group STPS. Effectiveness of add-on stiripentol to clobazam and valproate in Japanese patients with Dravet syndrome: additional supportive evidence. Epilepsy Res. 2014;108(4):725–731.
   PubMed Web of Science ®Google Scholar
• Jogamoto T, Yamamoto Y, Fukuda M, et al. Add-on stiripentol elevates serum valproate levels in patients with or without concomitant topiramate therapy. Epilepsy Res. 2017;130:7–12.
   PubMed Web of Science ®Google Scholar
• Levy RH, Lin HS, Blehaut HM, et al. Pharmacokinetics of stiripentol in normal man: evidence of nonlinearity. J Clin Pharmacol. 1983;23(11–12):523–533.
   PubMed Web of Science ®Google Scholar
• Peigne S, Chhun S, Tod M, et al. Population pharmacokinetics of stiripentol in paediatric patients with Dravet syndrome treated with stiripentol, valproate and clobazam combination therapy. Clin Pharmacokinet. 2018;57(6):739–748.
   PubMed Web of Science ®Google Scholar
• Peigne S, Rey E, Le Guern ME, et al. Reassessment of stiripentol pharmacokinetics in healthy adult volunteers. Epilepsy Res. 2014;108(5):909–916.
   PubMed Web of Science ®Google Scholar
• Levy RH, Loiseau P, Guyot M, et al. Michaelis-Menten kinetics of stiripentol in normal humans. Epilepsia. 1984;25(4):486–491.
   PubMed Web of Science ®Google Scholar
• Moreland TA, Astoin J, Lepage F, et al. The metabolic fate of stiripentol in man. Drug Metab Dispos. 1986;14(6):654–662.
   PubMed Web of Science ®Google Scholar
• May TW, Boor R, Mayer T, et al. Concentrations of stiripentol in children and adults with epilepsy: the influence of dose, age, and comedication. Ther Drug Monit. 2012;34(4):390–397.
   PubMed Web of Science ®Google Scholar
• Martinez-Lage JLPLR. Clinical antiepileptic efficacy of stiripentol in resistant partial epilepsies. Epilepsia. 1984;25:673.
   Web of Science ®Google Scholar
• Rascol O, Squalli A, Montastruc JL, et al. A pilot study of stiripentol, a new anticonvulsant drug, in complex partial seizures uncontrolled by carbamazepine. Clin Neuropharmacol. 1989;12(2):119–123.
   PubMed Web of Science ®Google Scholar
• Kassai B, Chiron C, Augier S, et al. Severe myoclonic epilepsy in infancy: a systematic review and a meta-analysis of individual patient data. Epilepsia. 2008;49(2):343–348.
   PubMed Web of Science ®Google Scholar
• Thanh TN, Chiron C, Dellatolas G, et al. [Long-term efficacy and tolerance of stiripentaol in severe myoclonic epilepsy of infancy (Dravet‘s syndrome)]. Arch Pediatr. 2002;9(11):1120–1127.
   PubMed Web of Science ®Google Scholar
• Inoue Y, Ohtsuka Y, Group STPS. Long-term safety and efficacy of stiripentol for the treatment of Dravet syndrome: a multicenter, open-label study in Japan. Epilepsy Res. 2015;113:90–97.
   PubMed Web of Science ®Google Scholar
• Wirrell EC, Laux L, Franz DN, et al. Stiripentol in Dravet syndrome: results of a retrospective U.S. study. Epilepsia. 2013;54(9):1595–1604.
   PubMed Web of Science ®Google Scholar
• Myers KA, Lightfoot P, Patil SG, et al. Stiripentol efficacy and safety in Dravet syndrome: a 12-year observational study. Dev Med Child Neurol. 2018;60(6):574–578.
   PubMed Web of Science ®Google Scholar
• Chiron C, Helias M, Kaminska A, et al. Do children with Dravet syndrome continue to benefit from stiripentol for long through adulthood?. Epilepsia. 2018;59(9):1705–1717.
   PubMed Web of Science ®Google Scholar
• Phillips NK, Lockard JS. Phenytoin and/or stiripentol in pregnancy: infant monkey hyperexcitability. Epilepsia. 1993;34(6):1117–1122.
   PubMed Web of Science ®Google Scholar
• Strzelczyk A, Schubert-Bast S, Reese JP, et al. Evaluation of health-care utilization in patients with Dravet syndrome and on adjunctive treatment with stiripentol and clobazam. Epilepsy Behav. 2014;34:86–91.
   PubMed Web of Science ®Google Scholar
• Elliott J, McCoy B, Clifford T, et al. Economic evaluation of stiripentol for Dravet syndrome: A cost-utility analysis. Pharmacoeconomics. 2018;36:1253–1261.
   PubMed Web of Science ®Google Scholar